SynthesisMedicine2026

Efficacy, safety and outcome of selective IL-23 inhibitor risankizumab in induction and maintenance of CD and ulcerative colitis: A systematic review.

Muhammad Waqas Afzal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.